Daiichi Sankyo Company, Limited announced that it has entered into an exclusive licensing agreement (hereinafter, the Agreement) with Esperion Therapeutics, Inc. to market bempedoic acid, their proprietary oral once-daily drug for the treatment of hypercholesterolemia, in South Korea, Brazil, Taiwan, Hong Kong, Macao, Thailand, Vietnam, Myanmar and Cambodia .
- Read more about Daiichi Sankyo joined with Espiron to market hypercholesterolemia medicine
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/daiichi-sankyo-joined-with-espiron-to-market-hypercholesterolemia-medicine
No comments:
Post a Comment